| scholarly article | Q13442814 |
| P50 | author | Giorgio Mottola | Q39505180 |
| P2093 | author name string | Bian Wu | |
| Michael S Conte | |||
| Anuran Chatterjee | |||
| Mian Chen | |||
| P2860 | cites work | Phosphorylation of the vasodilator-stimulated phosphoprotein regulates its interaction with actin | Q28140147 |
| Paxillin and focal adhesion signalling | Q28142041 | ||
| Phosphorylation of the integrin alpha 4 cytoplasmic domain regulates paxillin binding | Q28215040 | ||
| Classification, epidemiology, risk factors, and natural history of peripheral arterial disease | Q28218025 | ||
| Resolvin D1 and its aspirin-triggered 17R epimer. Stereochemical assignments, anti-inflammatory properties, and enzymatic inactivation | Q28218126 | ||
| The pro-resolving lipid mediator maresin 1 (MaR1) attenuates inflammatory signaling pathways in vascular smooth muscle and endothelial cells | Q28397861 | ||
| Role of endogenous platelet-derived growth factor in arterial smooth muscle cell migration after balloon catheter injury | Q28570843 | ||
| Phosphorylation of P-Rex1 by the cyclic AMP-dependent protein kinase inhibits the phosphatidylinositiol (3,4,5)-trisphosphate and Gbetagamma-mediated regulation of its activity | Q30438741 | ||
| Prolonged vasoconstriction of resistance arteries involves vascular smooth muscle actin polymerization leading to inward remodelling | Q30539871 | ||
| cAMP inhibits migration, ruffling and paxillin accumulation in focal adhesions of pancreatic ductal adenocarcinoma cells: effects of PKA and EPAC. | Q30566337 | ||
| Pro-resolving lipid mediators are leads for resolution physiology | Q30829097 | ||
| Identification and signature profiles for pro-resolving and inflammatory lipid mediators in human tissue | Q33840123 | ||
| Aspirin-Triggered Resolvin D1-modified materials promote the accumulation of pro-regenerative immune cell subsets and enhance vascular remodeling | Q33907380 | ||
| Resolvin E1 selectively interacts with leukotriene B4 receptor BLT1 and ChemR23 to regulate inflammation | Q50336774 | ||
| Sustained benefit at 2 years of primary femoropopliteal stenting compared with balloon angioplasty with optional stenting. | Q51004193 | ||
| Exendin-4 alleviates angiotensin II-induced senescence in vascular smooth muscle cells by inhibiting Rac1 activation via a cAMP/PKA-dependent pathway. | Q54316655 | ||
| Delayed exposure to pulsatile shear stress improves retention of human saphenous vein endothelial cells on seeded ePTFE grafts | Q70164847 | ||
| Platelet-derived growth factor is a chemoattractant for vascular smooth muscle cells | Q72684288 | ||
| Pathobiology of intimal hyperplasia | Q72787481 | ||
| Activation of cAMP-PKA signaling in vivo inhibits smooth muscle cell proliferation induced by vascular injury | Q73486413 | ||
| Synergistic inhibition of vascular smooth muscle cell migration by phosphodiesterase 3 and phosphodiesterase 4 inhibitors | Q74518955 | ||
| Results of PREVENT III: a multicenter, randomized trial of edifoligide for the prevention of vein graft failure in lower extremity bypass surgery | Q83157466 | ||
| Trends in the national outcomes and costs for claudication and limb threatening ischemia: angioplasty vs bypass graft | Q84862950 | ||
| Aspirin-triggered lipoxin and resolvin E1 modulate vascular smooth muscle phenotype and correlate with peripheral atherosclerosis | Q34162546 | ||
| Comparison of global estimates of prevalence and risk factors for peripheral artery disease in 2000 and 2010: a systematic review and analysis | Q34361910 | ||
| Resolvin D1 limits 5-lipoxygenase nuclear localization and leukotriene B4 synthesis by inhibiting a calcium-activated kinase pathway. | Q34407602 | ||
| Cutting edge: maresin-1 engages regulatory T cells to limit type 2 innate lymphoid cell activation and promote resolution of lung inflammation | Q34455625 | ||
| MicroRNAs in resolution of acute inflammation: identification of novel resolvin D1-miRNA circuits | Q34502699 | ||
| Novel lipid mediators promote resolution of acute inflammation: impact of aspirin and statins | Q34522097 | ||
| Specialized proresolving lipid mediators in patients with coronary artery disease and their potential for clot remodeling | Q34523903 | ||
| Platelet-derived growth factor promotes smooth muscle migration and intimal thickening in a rat model of balloon angioplasty | Q35597681 | ||
| Systemic delivery of proresolving lipid mediators resolvin D2 and maresin 1 attenuates intimal hyperplasia in mice | Q35660086 | ||
| β2-adrenergic receptor agonists modulate human airway smooth muscle cell migration via vasodilator-stimulated phosphoprotein | Q35684763 | ||
| Regulation of actin-based cell migration by cAMP/PKA. | Q35832749 | ||
| Vascular inflammation and repair: implications for re-endothelialization, restenosis, and stent thrombosis | Q35927338 | ||
| Resolvin D1 receptor stereoselectivity and regulation of inflammation and proresolving microRNAs | Q35951840 | ||
| Role of cAMP-phosphodiesterase 1C signaling in regulating growth factor receptor stability, vascular smooth muscle cell growth, migration, and neointimal hyperplasia | Q36433005 | ||
| Resolution phase of inflammation: novel endogenous anti-inflammatory and proresolving lipid mediators and pathways | Q36647303 | ||
| Mechanisms of vascular smooth muscle cell migration | Q36761041 | ||
| D-series resolvin attenuates vascular smooth muscle cell activation and neointimal hyperplasia following vascular injury | Q36860274 | ||
| Role of Rac in controlling the actin cytoskeleton and chemotaxis in motile cells | Q36967433 | ||
| Vascular smooth muscle cell motility: From migration to invasion | Q37832151 | ||
| Understanding resolvin signaling pathways to improve oral health | Q38093013 | ||
| National trends in lower extremity bypass surgery, endovascular interventions, and major amputations | Q38381318 | ||
| Epidemiology of peripheral artery disease | Q38440236 | ||
| National health care costs of peripheral arterial disease in the Medicare population | Q38455005 | ||
| Perivascular delivery of resolvin D1 inhibits neointimal hyperplasia in a rat model of arterial injury | Q39872912 | ||
| The role of VASP in regulation of cAMP- and Rac 1-mediated endothelial barrier stabilization | Q40055078 | ||
| Migration of human vascular endothelial and smooth muscle cells | Q40233092 | ||
| A requirement for rac1 in the PDGF-stimulated migration of fibroblasts and vascular smooth cells. | Q41022472 | ||
| Smooth muscle migration in atherosclerosis and restenosis | Q41669917 | ||
| Inability to resolve specific infection generates innate immunodeficiency syndrome in Xiap-/- mice | Q41752725 | ||
| The cAMP-producing agonist beraprost inhibits human vascular smooth muscle cell migration via exchange protein directly activated by cAMP. | Q41941935 | ||
| PKA modulation of Rac in neuronal cells | Q42943768 | ||
| Prevalence of and risk factors for peripheral arterial disease in the United States: results from the National Health and Nutrition Examination Survey, 1999-2000. | Q44450748 | ||
| Molecular pathways: P-Rex in cancer. | Q45163195 | ||
| Aspirin-triggered resolvin D1 inhibits TGF-β1-induced EMT through the inhibition of the mTOR pathway by reducing the expression of PKM2 and is closely linked to oxidative stress | Q46495715 | ||
| Regulation of human vascular smooth muscle cell migration by beta-adrenergic receptors | Q46957177 | ||
| Resolvin D1 stimulates alveolar fluid clearance through alveolar epithelial sodium channel, Na,K-ATPase via ALX/cAMP/PI3K pathway in lipopolysaccharide-induced acute lung injury | Q47896470 | ||
| Resolvin D1-mediated NOX2 inactivation rescues macrophages undertaking efferocytosis from oxidative stress-induced apoptosis | Q48004057 | ||
| P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P4510 | describes a project that uses | ImageJ | Q1659584 |
| P433 | issue | 3 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | aspirin | Q18216 |
| aspirin-triggered resolvin D1 | Q27074550 | ||
| P304 | page(s) | e0174936 | |
| P577 | publication date | 2017-03-31 | |
| P1433 | published in | PLOS One | Q564954 |
| P1476 | title | Aspirin-triggered resolvin D1 attenuates PDGF-induced vascular smooth muscle cell migration via the cyclic adenosine monophosphate/protein kinase A (cAMP/PKA) pathway | |
| P478 | volume | 12 |
| Q99585981 | Formyl peptide receptor type 2 agonists to kick-start resolution pharmacology |
| Q64898835 | Identification and structure elucidation of the pro-resolving mediators provides novel leads for resolution pharmacology. |
| Q59328896 | Lipoxin and Resolvin Receptors Transducing the Resolution of Inflammation in Cardiovascular Disease |
| Q55514888 | PDn-3 DPA Pathway Regulates Human Monocyte Differentiation and Macrophage Function. |
| Q64894558 | Perivascular delivery of resolvin D1 inhibits neointimal hyperplasia in a rabbit vein graft model. |
| Q91559617 | Phosphoproteomic analysis sheds light on intracellular signaling cascades triggered by Formyl-Peptide Receptor 2 |
| Q45064553 | Resolution of vascular injury: Specialized lipid mediators and their evolving therapeutic implications |
Search more.